PFSA (Profusa) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)


PFSA Profusa Inc PFSA
8 GF Score
Price $2.10
! 3 Warning Signs
View Full Analysis

What is Profusa LT-Debt-to-Total-Asset?

Profusa PFSA -16.54% 8 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates PFSA with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Profusa's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Profusa's long-term debt to total assets ratio stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00).

Profusa  (NAS:PFSA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Profusa LT-Debt-to-Total-Asset Related Terms

Profusa LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Profusa's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Profusa LT-Debt-to-Total-Asset Chart

Profusa Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.73 0.00 0.00 0.00 2.09

Profusa Quarterly Data
Dec21 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 3.38 2.09 0.00
PFSA
8GF Score
Profusa Inc PFSA
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Profusa LT-Debt-to-Total-Asset Calculation

Profusa's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=7.877/3.775
=

Profusa's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=0/0.862
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Profusa (PFSA) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Profusa and its competitors.
Is Profusa's LT-Debt-to-Total-Asset too high?
Profusa's current LT-Debt-to-Total-Asset is 0.00. Overall, Profusa has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Profusa's LT-Debt-to-Total-Asset compare to ODYY and SSKN?
Profusa's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Profusa and its competitors. Profusa's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profusa stock overvalued right now?
Profusa (PFSA) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Profusa's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Profusa (PFSA), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Profusa Business Description

Address 626 Bancroft Way, Suite A, Berkeley, CA, USA, 94710
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
8GF Score

Get the complete analysis for PFSA

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.10
Price